The persistent debate over whether or not fisetin is bioavailable or not is a suprise to me. As I reported back in post208 I experienced three very distinct effects which were attributable to either known properties of fisetin or senolytics (after my first dose osris). First of all my breathing improved dramatically the following day after struggling badly for months.(Fisetin inhibiting mast cells and another users experience.) I had no prior knowledge of this property. My problematic, likely arthritic knee weakened considerably (another contributor reported the same, and it has been a consistent personal fisetin effect), then eventually strengthened above prior baseline - we know senolytic, UBX0101, can treat arthritis and trigger cartilage regrowth in mice. Several people I've known who've taken small doses of Fisetin have experienced minor detox symptoms. Then of course there was the bleeding. Once again a known property senolytics is delayed wound healing.
These three effects were quite dramatic and a clear indication that fisetin was bioavailable when taken on that occasion. What is also clear is that the expression of this bioavailability would not be experienced by everyone, unless they had arthritic knees, raised levels of histamine and an untimely wart cut. As for the risk of bleeding, which is the one symptom I have some measure of doubt over as there might possibly be some other explanation* and it was not repeated, it does appear to be a transient risk, at least with me. I certainly cannot confirm whether the window of risk is repeatable, but, if it is there, it is only a window, at least personally. My breathing has remained excellent, although this has been confounded subsequently with zinc supplementation and the knee weakness a consistent response to the fisetin dose.
I believe there may have been other benefits but I am far too unsure to confidently assert them such as better skin and flexibility but they definitely subjective and there is quite simply far too much noise with other protocols and most definitely not night and day effects: these were. Lost would indicate that he has had those experiences, but he has been comparatively off the scale in net-dosing. His most pronounced observation was probably the need for anti-biotics over 16 days after a skin infection - it is a chance anecdote and not necessarily attributable to fisetin, but it is an outlier of an effect.
As for comparing with D+Q unless they are targeting the same senescent cells, why would we expect comparable effects?
*as well as proximity to dose, a week later or so.
Edited by ambivalent, 23 October 2019 - 03:26 PM.